Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
HYDROCORTISONE BUTYRATE
PCO Manufacturing
0.1 %w/w
Cream
2006-11-10
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PPA0465/177/001 Case No: 2054664 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PCO MANUFACTURING LIMITED UNIT 10, ASHBOURNE BUSINESS PARK, RATH, ASHBOURNE, CO. MEATH, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product LOCOID 0.1 % W/W CREAM The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 20/10/2008 until 09/11/2011. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 20/10/2008_ _CRN 2054664_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Locoid 0.1% w/w Cream 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The cream contains 0.1% w/w Hydrocortisone Butyrate Excipients: Cetostearyl Alcohol Propyl parahydroxybenzoate (E216) Butyl parahydroxybenzoate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cream _Product imported from France:_ A white, aqueous-based cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in pso Read the complete document